D. E. Shaw & Co., Inc. Altimmune, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 354,350 shares of ALT stock, worth $2.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
354,350
Previous 289,726
22.31%
Holding current value
$2.23 Million
Previous $3.26 Million
10.68%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ALT
# of Institutions
185Shares Held
44.7MCall Options Held
1.1MPut Options Held
647K-
State Street Corp Boston, MA8.65MShares$54.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.04MShares$25.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.13MShares$19.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$17.3 Million3.41% of portfolio
-
Morgan Stanley New York, NY2.21MShares$13.9 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $308M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...